Latin America has been fighting to advance health care access for HIV patients since the 1980s. Colombia’s Ministry of Health has officially recognized the importance of Colombia’s HIV treatment plans in addressing patent barriers and high costs. This acknowledgment aims to ensure public access to affordable HIV medication, specifically Dolutegravir (DTG). In October 2023, the Colombian government made a “landmark decision to declare the HIV medicine Dolutegravir of public interest, allowing the country to purchase or manufacture more affordable, generic versions of the live-saving HIV medicine,” UNAIDS reported. Here is how HIV/AIDS in Colombia is being treated.

The Breakthrough of Affordable Treatment

Countries such as Costa Rica, Argentina and Brazil have improved their access to HIV-related treatment with hopes of controlling the HIV/AIDS epidemic. Unfortunately, as of 2022, Colombia’s HIV prevalence of 0.5% was one of the highest in Latin America, with an estimated 190,000 infected adults. Colombia continues to face challenges, with 13.8% of its population earning less than $49 per month as of 2022.

In 2022, the poverty rate among Colombians decreased to 36.6%, translating to 18.3 million people out of the total population of 50 million. The proportion of people living in extreme poverty rose to 13.8%, amounting to around 6.9 million Colombians. 

However, the recent approval of Dolutegravir marks a significant advancement in Colombia’s approach to HIV treatment. The declaration challenges the pharmaceutical company, ViiV Healthcare, by allowing the import of low-cost generic versions of the HIV medicine without needing permission from the patent owner. This move enables the Colombian Government to issue a compulsory license, breaking the monopoly and making the medicine more affordable for both purchase and local manufacturing. This decision appears to be a crucial step in enhancing public health measures for HIV/AIDS treatment in Colombia.

Not only is generic Dolutegravir available internationally at a fraction of ViiV’s price, but the World Health Organization (WHO) recommends it as the preferred first-line treatment for people living with HIV, including pregnant individuals.

Treatments that utilize Dolutegravir-based medications have proved greater adherence due to fewer side effects while also presenting a reduced likelihood of drug resistance.

How HIV Treatment Access Could Impact Latin America

ViiV Healthcare excluded Colombia and other populous middle-income countries from being able to gain health advancements from the license, protecting its monopoly and its authority to charge higher prices for the medications. Now, Colombia’s declaration is going to help neighboring countries, such as Brazil, in gaining access to more affordable generics.

Issuing the compulsory license could mean that the price of the life-saving medicine is “reduced by as much as 80%.” With this decision, the Colombian government estimates that it will be able to prescribe 28 people with Dolutegravir for the same price that it is allocated today to treat just one person. The implementation of the declaration will allow the country to access less expensive, but just as effective, medications that are globally available. Projections have indicated there will be a large increase in reach with such quality medicines, benefitting HIV/AIDS treatment in Colombia and saving millions of lives.

This action is not only crucial for saving lives in Colombia but also holds significance for the broader Latin American region. Colombia currently hosts the largest population of Venezuelan migrants globally, with 2.9 million as of October 2022. These migrants rely on Colombian health resources. Recent studies indicate a 0.9% HIV prevalence among this group, nearly doubling the 0.5% prevalence in the country’s adult population. The decision allows the government to produce or obtain more cost-effective versions of the vital first-line antiretroviral treatment. This includes all people living with HIV in Colombia, encompassing Venezuelan migrants, emphasizes Luisa Cabal, UNAIDS Regional Director for Latin America and the Caribbean.

Colombia’s Stand for Global Health Equity and Systematic Change

As Colombia boldly steps into the forefront of challenging pharmaceutical norms, the declaration to make HIV medicines public interest, coupled with the pursuit of affordable generic treatments, marks a pivotal moment. Colombia’s commitment to offering equal health care redefines the standards of care for those in need of Colombia’s HIV treatment. This courageous move not only transforms the accessibility of life-saving medication but also sets a precedent for global health equity. These cases have served as an initiative for growth in health care litigation generally, an expansion of the concept of a right to health and systemic transformation.

– Samantha Rentfro
Photo: Wikipedia Commons